Company Analysis Northwest Biotherapeutics, Inc.
1. Summary
Advantages
- Price (0.53 $) is less than fair price (0.5392 $)
- The stock's return over the last year (-23.19%) is higher than the sector average (-33.06%).
- Current debt level 146.39% has decreased over 5 years from 187.85%.
- The company's current efficiency (ROE=95.17%) is higher than the sector average (ROE=12.96%)
Disadvantages
- Dividends (0%) are below the sector average (1.73%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Northwest Biotherapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 82.8% | -2.2% | 0.6% |
| 90 days | 35.9% | -41% | 7% |
| 1 year | -23.2% | -33.1% | 31.9% |
NWBO vs Sector: Northwest Biotherapeutics, Inc. has outperformed the "Healthcare" sector by 9.88% over the past year.
NWBO vs Market: Northwest Biotherapeutics, Inc. has significantly underperformed the market by -55.08% over the past year.
Stable price: NWBO is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: NWBO with weekly volatility of -0.4459% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.53 $) is lower than the fair price (0.5392 $).
Price not significantly lower than the fair price: The current price (0.53 $) is slightly lower than the fair price by 1.7%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (117.69).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (53.07).
4.3. P/BV
P/BV vs Sector: The company's P/BV (-13.4) is lower than that of the sector as a whole (3.37).
P/BV vs Market: The company's P/BV (-13.4) is lower than that of the market as a whole (-9.1).
4.4. P/S
P/S vs Sector: The company's P/S indicator (456.31) is higher than that of the sector as a whole (8.16).
P/S vs Market: The company's P/S indicator (456.31) is higher than that of the market as a whole (5.18).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-9.03) is lower than that of the sector as a whole (52.39).
EV/Ebitda vs Market: The company's EV/Ebitda (-9.03) is lower than that of the market as a whole (23.95).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 41.67% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (41.67%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-73.51%).
5.4. ROE
ROE vs Sector: The company's ROE (95.17%) is higher than that of the sector as a whole (12.96%).
ROE vs Market: The company's ROE (95.17%) is higher than that of the market as a whole (-2.01%).
5.5. ROA
ROA vs Sector: The company's ROA (-224.65%) is lower than that of the sector as a whole (6.09%).
ROA vs Market: The company's ROA (-224.65%) is lower than that of the market as a whole (8.98%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.03%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.73%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
